

Index

Page numbers in *italics* represent figures, those in **bold** represent tables.

- ABCDE approach, 11–13, 25, 48, 68
abscesses, 59, **59**
activated protein C, 71–2
acute cholecystitis, 60
acute lung injury (ALI), 69, 80
acute renal failure (ARF), 17, 24, 72
acute respiratory distress syndrome (ARDS), 16, 19, 64–5, 80–1, 81
acute tubular necrosis (ATN), 17, 24
AIDS, 62–3, **63**
airway, 11–2
allergy, to antibiotics, 33
anastomotic leak, 11, 57–8, 58
antibiotic resistance, 35
antibiotic therapy, 29, 30, 30, 32–5
 choice of empiric antimicrobials, 32–3, 35
 endocarditis, 55
 immunocompromised patients, 65–6, 65, **66**
 pneumonia, 51, 51
 prudent use, 38
antifungal agents, 66, **66**
antiviral agents, 66, **66**
arterial waveform analysis, 75–6
aseptic no-touch technique (ANTT), 39
aspiration pneumonia, 52
AVPU scale, 13
AXR (abdominal X-ray), 43
- bacteria, in immunocompromised patients, 63
barrier nursing, 63
barriers, to changing behaviour, 84–5, **85**
 β_2 -agonists, 80
biomarkers, 4
blood cultures, 30–2, 30, **32**, 64
 contamination, 33, 39
 organisms isolated from, 33, **33**
blood pressure monitoring, 73–4, **74**
blood tests, 27, 76–7
breathing, 12
- cannulation, 26
cardiac output monitoring, 75–6
cardiovascular complications, 15
cardiovascular monitoring, 73–5
cardiovascular support, 71
care bundles, 68–9, **68**, 84
cellular response to infection, 21–2
cellulitis, 49, 49
- central nervous system complications, 17–18
 central venous catheters (CVCs), 27, 40, 71
 central venous pressure (CVP) monitoring, 74–5, **74**
central venous oxygen saturation (ScvO₂), 76–7
change, approaches to, 83–6
chronic obstructive pulmonary disease (COPD), 51–2
circulation, 12
circulatory system, in sepsis, 23
clinical assessment, 11–13
clinical monitoring, 73
clinical signs, 24, **24**
Clostridium difficile, 36–8, 55, 60–1
Clostridium difficile colitis, 60–1
coagulation defects, 2–3, 3, 17, 77
cohort nursing, 37
communication, 13–14
community-acquired pneumonia (CAP), 32–3, 49, 51
compensatory anti-inflammatory response syndrome (CARS), 23
complications, 15–19, 17
computerized tomography (CT), 42, **42**, 44–5, **45**, 65, 65
contamination, from skin, 33
continuous positive airway pressure (CPAP), 69, 69, 74
critical care, 63–7, 15
critical illness polyneuropathy, 18
CRP, 32
CURB score, 51
CXR, 42–3, **42**, 51
cytokines, 2, 2, 21–3, 21
cytomegalovirus (CMV), 63–6, 63, **66**
- de-escalation, 34
diabetic foot, 59–60
diagnostic challenges, 2–3
diagnostic criteria, 7–8, **7**, **8**
diarrhoeal illnesses, 55, 60
diffuse alveolar damage (DAD), 15–16
disability (as part of ABCDE assessment), 12–13
disseminated intravascular coagulation (DIC), 77, 17
drotrecogin alfa (activated), 71
Dukes University criteria, 55
- early goal-directed therapy (EGDT), 27, 68, 71
echocardiography, 76, **76**
electrocardiographic (ECG) monitoring, 73
empyema, 42, 44–5, 51
encephalitis, 54
endocarditis, 12, 54–5
endothelium, 4, 17, 21–2, 21
environment, 38
epidemics, 33
ethyl pyruvate, 81
European Antimicrobial Resistance Surveillance System (EARRS), 36
Evaluation for Severe Sepsis Screening Tool, 6
Exposure (as part of ABCDE assessment), 13
- feeding lines, 40
fluid challenges, 27
fungaemia, 6
fungi, in immunocompromised patients, 64
future directions, 3–4
- gadolinium enhancement, 45
gallbladder, 47, 60
gastrointestinal complications, 18
genetic influences, 79
Glasgow Coma Score, 13
glucose control, 71
GRADE system, 84
gram-negative organisms, 17, 21, 35, **35**, 63
gram-positive organisms, 17, 35, **35**, 60, 63
- H1N1 influenza ('swine flu'), 67
haemoglobin, 27, 69
hand washing, 37
health worker vaccinations, 38
healthcare-associated infection (HCAI), 36–9
heart, in sepsis, 23–4
HMG-CoA reductase, 80, 80
HMGB-1, 3, 81
hospital-acquired pneumonia (HAP), 32–3, 50
human immunodeficiency virus (HIV), 51, 54, 62–5, **62**
humoral response, 22
hypoxaemia, 12, 16
- imaging, 42–7, **42**, **45**, 46
immunocompromised patients, 62–7, 65
immunodeficiency, causes, 62, **62**
immunological complications, 18

- improvement project, planning, 85–6
- infection,
 definition, 6
 sources, 8, 8, 61, 69
- infection control (IC), 29, 36–40, 72
- inflammation, definition, 5
- inflammatory markers, 32, 77
- innate immune system, 20–1, 21
- intermittent positive pressure ventilation (IPPV),
 24, 69
- interventional radiology, 46–7
- interventions, 38–9, 83–4
- intravenous broad-spectrum antibiotics, 27–8, 33
- intravenous immunoglobins (IVIGs), 79–80
- investigations, 13, 32
- iodinated contrast, 44–5
- isolation, 37–8
- kidney, in sepsis, 17, 24
- knowledge transfer, 3, 83–6, 84
- lactate, measurement, 27, 77
- Legionella pneumophila*, 33
- leukocyte reprogramming, 23
- limb complications, 18
- limitation of support, 72
- line-related sepsis, 39–40, 52
- lumbar puncture (LP), 13, 45, 54
- lung, in sepsis, 24, 15–16, 16
- magnetic resonance imaging (MRI), 42, 42, 45–6,
 45, 46
- Management Bundle, 68–9
- management of surgical patient, 61
- Mannheim Peritonitis Index, 57, 57
- meningitis, 45, 52–4
- MEWS, 7, 7, 11, 11
- microbiological sampling, 29–32
- microbiology, 29–35, 30
- mitochondria, 22
- mixed venous saturation (SvO₂), 76
- monitoring, 70–1, 73–7, 74
- mortality, 1, 5, 8, 15–16, 16
- MRSA, 32, 36–7, 38
- multi-organ dysfunction syndrome (MODS), 15
- mycoplasma pneumonia, 33
- myocardial depression, 2, 15, 23, 23
- necrotizing fasciitis, 50, 60, 60
- neutropenia, 62–6, 62, 63
- nomenclature, 5
- novel therapies, 78–82
- nuclear medicine, 42, 42, 46
- nutritional support, 72
- oesophageal Doppler (OD), 75, 75, 75
- organ dysfunction, diagnostic criteria, 8
- organizational factors, 84–5
- osteomyelitis, 45, 50, 59
- oxygen, high-flow, 26
- pandemics, 33
- pathophysiology, 1–2, 20–4, 23
- patient environment action teams (PEATs), 38
- Procalcitonin (PCT), 32
- percutaneous drainage, 46–7, 47, 60
- perforated viscus, 58
- peripheral venous cannulae (PVCs), 39
- peritonitis, 57–8, 57, 58
- persistent sepsis, 34–5
- personal protective equipment (PPE), 40
- pharmacogenomics, 79
- phlebitis, 39, 52–3, 53
- PIRO, 1, 8
- plain radiography, 42–3, 42
- Plan-Do-Study-Act (PDSA) cycles, 85
- Pneumocystis carinii* pneumonia (PCP),
 65–6
- pneumonia, 50–2, 51
- polyclonal immunoglobins, 79–80
- presentations,
 in immunocompromised patients, 64
 in medical patients, 48–55
 in surgical patients, 57–61
- pro-inflammatory responses to infection, 20
- protective isolation, 37, 63
- psychological complications, 18–19
- pulmonary artery flotation catheters
 (PAFC), 75
- pulse oximetry, 12, 26, 76–7, 76
- pulse pressure variation (PPV), 76, 76
- purpura fulminans, 18, 18, 52–3
- pyelonephritis, 49
- pyonephrosis, 46
- quality improvement (QI), 83–6
- reliability improvement, 83–5
- renal complications, 17
- renal replacement therapies (RRTs), 17, 72
- respiratory complications, 15–16
- resuscitation, 25–8, 48, 71
- Resuscitation Bundle, 3, 68–9, 84
- retroperitoneum, 44
- SBAR, 13–14
- screening tools, 8, 10
- sepsis-associated encephalopathy
 (SAE), 17–18
- ‘Sepsis Six’, 26, 48
- septic arthritis, 59
- septic shock, definition, 6
- severe acute pancreatitis, 60
- severe sepsis,
 causes, 10
 definition, 6
 recognition, 10–1
- Severe Sepsis Screening Tools, 8, 10–1
- sharps, disposal, 38
- signs and symptoms of infection, 6
- SIRS, 1, 5–7, 6, 7, 7, 15–16, 16, 60, 77
- source isolation, 63
- staphylococcal infection, 33
- statins, 80, 80
- steroids, low-dose, 71
- stroke volume variation (SVV), 76
- surgical intervention, 61
- surveillance, 36–7
- Surviving Sepsis Campaign (SSC), 3, 68, 74, 78,
 83–6
- systemic inflammatory response syndrome *see*
 SIRS,
- therapeutic targets/agents, 3, 78–9
- tissue perfusion, 22
- TLRs, 1, 21, 21
- tools, for improvement, 85
- track-and-trigger scoring systems, 11
- treatment, unsuccessful, 20, 20
- trials, 3, 78
- tuberculous (TB) meningitis, 54, 54
- ultrasound, 42–4
- uniforms, 38
- urinary catheters, 28, 40, 49
- urinary tract infections (UTIs), 48–9
- vascular access, 26, 70–1
- vascular endothelium, 21–2
- ventilation, 69–70, 69, 70
- ventilator-induced lung injury (VILI), 69–70
- viruses, in immunocompromised patients, 64
- Visual Infusion Phlebitis (VIP) score, 39,
 52–3, 53
- white cell count, 32
- wound infections, 58